Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir

• Main Authors: Rahmet Guner (Author), Imran Hasanoglu (Author), Bircan Kayaaslan (Author), Adalet Aypak (Author), Esragul Akinci (Author), Hurrem Bodur (Author), Fatma Eser (Author), Ayse Kaya Kalem (Author), Orhan Kucuksahin (Author), Ihsan Ates (Author), Aliye Bastug (Author), Yasemin Tezer Tekce (Author), Zeynep Bilgic (Author), Fahriye Melis Gursoy (Author), Hatice Nisa Akca (Author), Seval Izdes (Author), Deniz Erdem (Author), Emra Asfuroglu (Author), Habibe Hezer (Author), Hatice Kilic (Author), Musa Cıvak (Author), Sibel Aydogan (Author), Turan Buzgan (Author)
• Format: Book
• Published: Elsevier, 2021-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: In this study, we aimed to compare the intensive care unit (ICU) admission rate of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ), favipiravir, and HCQ plus favipiravir. Methods: Single center retrospective designed observational study conducted in Ank...